



Adrenal Incidentaloma

10th Nov 2017

Prof. Fahmy Hanna




Pilgrim not an Expert

- **Objectives: To share**
 - **Sign-post available evidence:**
 - European Society of Endocrinology guidelines, 2016
 - Review for the generalist: in press
 - **Share our experience:**
 - The challenges identified
 - Steps we have taken so far
 - Solutions
 - **Gauge your thoughts/ideas**

Hope to leave you with more Q to reflect on!



AI Management Overview;



¹For patients with history of extra-adrenal malignancy, see special section 5.6.4.
²Only in patients with concomitant hypertension and/or hypokalemia.
³Only in patients with clinical or imaging features suggestive of adrenocortical carcinoma.



Fassnacht et al. Eur J Endocrinol 2016;175:G1-G34

AI; Overview

- **Definition:**
 - An adrenal mass, >10mm, detected on imaging which was not performed for suspected adrenal disease
- **Mostly, benign and non functioning:**

Classification (Series including all patients with Ad mass)	Median (%)	Range
Adenoma	80	30-96
Non-functioning	75	
Cortisol-secreting	12	
Aldosterone-secreting	2.5	
Phaeochromocytoma	7.0	
Adrenocortical Cancer	8.0	1.2-11
Metastasis	5.0	



AI; Real World Challenges

1. Uncertainties

2. Workload

3. Process



AI; Real World Challenges

(1) Uncertainties

- Identified whilst looking for something else, by a “non-expert” (an unexpected extra hurdle)
- Uncertainties facing the “expert”:
 - Why: Guidelines are mostly based on case series/expert opinions (> 80% low level)
 - Examples:
 - What about lesions 0.9 cm?
 - Are cut-off values for screening appropriate for AI as they have been in Cushing’s, Conn’s or Phaeo?



AI; Real World Challenges;

(2) Workload

NHS

University Hospitals
of North Midlands
NHS Trust

- ~4-5% of all CT/MRI
 - Higher prevalence with age + Ageing population
 - More CT/MR in diagnostic pathways
- At UHNM; 12,000 scan PA (almost X4 in 6 years)
- Expected AI new cases: 450-600 PA
- Implications:
 - One third of our total endocrine contract!
 - Only ~30% get identified and referred on



PROUD
TO
CARE

AI; We Miss Almost 70% (Even with a dedicated MDT)

	Nov 2014	Nov 2015	Nov 2016
Total cases reported using the index phrases	57	76	77
Previously known malignancies (excluded)	30	41	15
Confirmed AIs	27	35	62
AIs referred	8	10	20
Percentage of AIs referred	29.6%	28.6%	32.3%



AI; Real World Challenges;

(3) Process

- Lack of standardised referral process:
 - Different sources
 - Variable information
 - Missed cases
- Limited “expert” capacity (Time/money):
 - Chase missing information
 - Chase outstanding results (Cortisol, ARR and plasma/urinary metanephrines are back separately at different times)
 - When all results are back, all findings have to be retrieved in preparation of MDT
 - MDT outcome to be shared and enacted (including further testing)
 - Further review of results as decided by MDT
- What to do with equivocal results (ONDST of 63, undetectable renin, slightly raised plasma normetanephrine, ...)



Our Approach

MDT

+

electronic AI Management System (eAIMS)

+

Patient Engagement



**PROUD
TO
CARE**

MDT

- **Prioritisation strategy; aligned to guidance**
- **Membership:**
 - Endocrinology/DM specialist
 - Radiologist (uro-, isotope-, intervention-)
 - Clinical biochemist
 - Urologist
 - Nephrologist
 - Pathologist
 - Anaesthetist (phaeochromocytoma)
- **Monthly meeting: & In between discussions**



Electronic AI Management System (eAIMS)

- **Successful Health Foundation- “I-4-I” Award**
- **Aim:**
 - Record all detail in one system (clinical + MDT)
 - Generate pre-populated outcome letter
 - Guide management (in progress)
- **Implementation:**
 - Successful development, security- and governance-checks concluded
 - Web-based to facilitate wider adoption.



eAIMS: Outcomes

- A 78% reduction in the time from AI identification to MDT decision → patient anxiety
- A 30% reduction in staff hands-on time.
- A 28% reduced cost (independent health economics analysis, UEA)
- Improved patient safety: Minimising risk of
 - Transcription errors
 - Missed cases



I1

Tony; it was 175 minutes and became 120 now
lenovo, 02/11/2017

Electronic AI Management System (eAIMS)



MDT/Clinic Outcome Letter

Diabetes and Endocrinology
Royal Stoke University Hospital
Please insert contact details
Newcastle Road
Stoke-on-Trent
ST4 6QG

13 Feb 2017

Dear Dr Dr Smithi,

Re: Xxxxxx Yyyyyyyy 16/08/1947 118 sfkslfj lksjf Isjfad, Kidsgrove, Staffs, XSSSS
Diagnosis: Left 15mm adrenal incidentaloma

Comorbidities:

Results:

Urea and electrolytes

Date	Sodium	Potassium	Urea	Creatinine	eGFR
12/07/2016	138 mmol/L	4.5 mmol/L	5.1 mmol/L	77 µmol/L	89 mL/min/1.73m ²
28/07/2016	140 mmol/L	3.9 mmol/L	5.2 mmol/L	79 µmol/L	90 mL/min/1.73m ²

Overnight dexamethasone suppression test

Date	Serum cortisol
12/07/2016	78 nmol/L

Aldosterone/Renin Ratio

Date	Aldosterone	Renin	Aldosterone/Renin Ratio
12/07/2016	69 pmol/L	-	-

Low-dose dexamethasone suppression test

Date	Cortisol Baseline	Cortisol End	ACTH Baseline	ACTH End	24 hour urinary free cortisol levels - Day 1	24 hour urinary free cortisol levels - Day 2	24 hour urinary free cortisol levels - Day 3	24 hour urinary free cortisol levels - Day 4
27/07/2016	692 mmol/l	71 mmol/l	27.4 pg/l	<5 pg/l	-	-	-	-

Plasma metadrenalines

Date	Plasma Normetadrenaline	Plasma Metadrenaline
12/07/2016	0.99 nmol/L	-

Salivary Cortisol

Date	Day 1 Morning	Day 1 Evening	Day 2 Morning	Day 2 Evening	Day 3 Morning	Day 3 Evening
31/08/2016	17.8 nmol/L	3.0 nmol/L	15.5 nmol/L	3.0 nmol/L	17.2 nmol/L	3.5 nmol/L

Reason for discussion Adrenal incidentaloma picked up on CT scan in March 2016 when being investigated for abdominal discomfort. MDT Outcome Repeat 2 day low dose Dexamethasone suppression test and salivary cortisol in 12 months. No further imaging required.

Way Forward

- Successfully secured 2nd Health Foundation “**Spreading Innovation**” grant:
- Applied for **Scaling up** (NIHR), waiting for outcome on outline bid. We aim to:
 - Spread the initiative in other pilot sites & reflect on the implementation process (Adaptive Learning)
 - Online Patient Portal with Q&A: ↓anxiet
 - Step-wise adoption by other collaborators

Happy for collaboration



Thank you for listening


Prof Tony Fryer (Co-Lead; Clin Biochem)
Dr Basil Issa (Manchester; Endo)
Dr Cherian George (Radiology)
Prof Julius Sim (Keele; Statistics)
Prof Ric Fordham (UEA; H Economics)
Mrs Helen Robertson (MDT Co-ord)
Mr Chris Hale (eAIMS developer)
Mrs Elloise Maddock (IT Business Mgr)
Mr Mike Firn (QI lead)
Dr John Oxtoby (MD)
Dr Seyi Ogunmekan (1ry Care Rep)
Mr Paul Tanner (Patient Representative)



**PROUD
TO
CARE**



Figure 2 Assessment and management of ‘autonomous cortisol secretion’ in patients with adrenal incidentalomas.



¹The majority of, but not all, panel members preferred additional biochemical tests to better judge the degree of cortisol secretion. In patients with comorbidities, we suggest to measure plasma ACTH and to repeat the dexamethasone test in 3–12 months.

²We suggest additional biochemical tests to better judge the degree of cortisol secretion: plasma ACTH, 24-h urinary-free cortisol, (and/or late-night salivary cortisol) and repetition of the dexamethasone test in 3–12 months.

³See Table 2 for potentially cortisol-related comorbidities.


⁴Choice for surgery should always be individualized.

⁵Need of follow-up by an endocrinologist for 2–4 years.



Martin Fassnacht et al. Eur J Endocrinol 2016;175:G1-G34

Figure 4 Evaluation of patients with adrenal mass and known extra-adrenal malignancy



¹Always take life expectancy in consideration.


²If there is hormone excess, treat individualized.

³FDG-PET-CT should be considered to exclude other metastatic deposits in patients with no other obvious metastatic lesions for whom surgical removal of the lesion is an option.

Martin Fassnacht et al. Eur J Endocrinol 2016;175:G1-G34



Figure 3 Flowchart on the management of adrenal masses considered for surgery. **NHS**



¹'Autonomous cortisol secretion' is not automatically judged as clinically relevant (see Section 5.3 for details).

²In tumors with benign radiological features and a tumor size >4 cm, surgery might also be individually considered(see text).

Martin Fassnacht et al. Eur J Endocrinol 2016;175:G1-G34

